Raymond James & Associates’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-13,435
| Closed | -$632K | – | 3860 |
|
|
2023
Q2 | $632K | Buy |
13,435
+3,719
| +38% | +$175K | ﹤0.01% | 2762 |
|
|
2023
Q1 | $408K | Buy |
9,716
+3,411
| +54% | +$143K | ﹤0.01% | 3012 |
|
|
2022
Q4 | $240K | Buy |
+6,305
| New | +$240K | ﹤0.01% | 3318 |
|
|
2021
Q2 | – | Sell |
-9,702
| Closed | -$726K | – | 3977 |
|
|
2021
Q1 | $726K | Sell |
9,702
-3,058
| -24% | -$229K | ﹤0.01% | 2719 |
|
|
2020
Q4 | $1.1M | Sell |
12,760
-83,725
| -87% | -$7.24M | ﹤0.01% | 2270 |
|
|
2020
Q3 | $5.9M | Buy |
96,485
+69,147
| +253% | +$4.23M | 0.01% | 1133 |
|
|
2020
Q2 | $1.14M | Buy |
27,338
+6,397
| +31% | +$266K | ﹤0.01% | 2066 |
|
|
2020
Q1 | $601K | Buy |
20,941
+12,331
| +143% | +$354K | ﹤0.01% | 2293 |
|
|
2019
Q4 | $622K | Sell |
8,610
-26,648
| -76% | -$1.93M | ﹤0.01% | 2559 |
|
|
2019
Q3 | $4.95M | Sell |
35,258
-2,133
| -6% | -$299K | 0.01% | 1231 |
|
|
2019
Q2 | $6.85M | Buy |
37,391
+4,284
| +13% | +$784K | 0.01% | 1062 |
|
|
2019
Q1 | $5.27M | Buy |
33,107
+10,602
| +47% | +$1.69M | 0.01% | 1159 |
|
|
2018
Q4 | $2.16M | Buy |
22,505
+631
| +3% | +$60.5K | ﹤0.01% | 1606 |
|
|
2018
Q3 | $3.09M | Buy |
21,874
+3,341
| +18% | +$472K | ﹤0.01% | 1533 |
|
|
2018
Q2 | $2.9M | Buy |
18,533
+4,304
| +30% | +$674K | ﹤0.01% | 1535 |
|
|
2018
Q1 | $2.29M | Sell |
14,229
-352
| -2% | -$56.7K | ﹤0.01% | 1620 |
|
|
2017
Q4 | $2.4M | Buy |
14,581
+414
| +3% | +$68.2K | ﹤0.01% | 1575 |
|
|
2017
Q3 | $883K | Sell |
14,167
-8,631
| -38% | -$538K | ﹤0.01% | 2172 |
|
|
2017
Q2 | $1.82M | Buy |
22,798
+8,561
| +60% | +$682K | ﹤0.01% | 1629 |
|
|
2017
Q1 | $1.01M | Sell |
14,237
-10,218
| -42% | -$726K | ﹤0.01% | 1972 |
|
|
2016
Q4 | $1.25M | Buy |
24,455
+17,051
| +230% | +$871K | ﹤0.01% | 1805 |
|
|
2016
Q3 | $341K | Buy |
+7,404
| New | +$341K | ﹤0.01% | 2525 |
|